BioAtla, Inc.
BCABNASDAQHealthcare● Active
$3.31
$-0.02(-0.60%)
Market Cap$4174023
P/E Ratio—
52W High$71.5
52W Low$3.12
BioAtla, Inc. (BCAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCAB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$6.18
Est. -$10.00 · +38.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
BCAB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$8.50 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$10.00 | -$6.18 | +38.2% | — | — | — |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$12.00 | -$8.00 | +33.3% | $0.00B | $0.00B | +185.7% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.31 | -$0.27 | +12.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.29 | -$0.31 | -6.9% | — | — | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.28 | -$0.29 | -3.6% | — | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.40 | -$0.32 | +20.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.34 | -$0.22 | +35.3% | $0.01B | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$8.50
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$6.18
EPS Est.
-$10.00
EPS Surpr.
+38.2%
Revenue
—
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$8.00
EPS Est.
-$12.00
EPS Surpr.
+33.3%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.27
EPS Est.
-$0.31
EPS Surpr.
+12.9%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.29
EPS Surpr.
-6.9%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.29
EPS Est.
-$0.28
EPS Surpr.
-3.6%
Revenue
—
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.40
EPS Surpr.
+20.0%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.22
EPS Est.
-$0.34
EPS Surpr.
+35.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-7.00 | $-7.00 | $-7.00 | 1 |
| Q3 FY2026 | $-7.00 | $-7.00 | $-7.00 | 1 |
| Q2 FY2026 | $-8.50 | $-8.50 | $-8.50 | 1 |
| Q1 FY2026 | $-10.00 | $-10.00 | $-10.00 | 1 |
| Q4 FY2025 | $-12.00 | $-12.00 | $-12.00 | 1 |
| Q3 FY2025 | $-0.30 | $-0.30 | $-0.30 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +38.2% | $4.37 | $4.27 | -2.29% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +33.3% | $7.70 | $8.05 | +4.55% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +12.9% | $34.39 | $32.99 | -4.07% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -6.9% | $18.73 | $19.00 | +1.44% |
| ▼ Q2 FY2025 | May 6, 2025 | -3.6% | $25.89 | $23.77 | -8.19% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +20.0% | $18.73 | $19.63 | +4.81% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +35.3% | $103.00 | $111.00 | +7.77% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +2.2% | $69.50 | $73.50 | +5.76% |
Q2 FY2026-2.29%
Report Date
May 15, 2026
EPS Beat/Miss
+38.2%
Price Before
$4.37
Price After
$4.27
Q1 FY2026+4.55%
Report Date
Mar 31, 2026
EPS Beat/Miss
+33.3%
Price Before
$7.70
Price After
$8.05
Q4 FY2025-4.07%
Report Date
Nov 13, 2025
EPS Beat/Miss
+12.9%
Price Before
$34.39
Price After
$32.99
Q3 FY2025+1.44%
Report Date
Aug 7, 2025
EPS Beat/Miss
-6.9%
Price Before
$18.73
Price After
$19.00
Q2 FY2025-8.19%
Report Date
May 6, 2025
EPS Beat/Miss
-3.6%
Price Before
$25.89
Price After
$23.77
Q1 FY2025+4.81%
Report Date
Mar 27, 2025
EPS Beat/Miss
+20.0%
Price Before
$18.73
Price After
$19.63
Q4 FY2024+7.77%
Report Date
Nov 7, 2024
EPS Beat/Miss
+35.3%
Price Before
$103.00
Price After
$111.00
Q3 FY2024+5.76%
Report Date
Aug 8, 2024
EPS Beat/Miss
+2.2%
Price Before
$69.50
Price After
$73.50
Avg Beat Reaction+2.76%
Avg Miss Reaction-3.38%
Beat Rate6 / 8 quarters
Largest Move-8.19% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCAB ends December
BioAtla, Inc. (BCAB) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-6.18 — beating the analyst consensus of $-10.00 by +38.2%. BCAB has beaten EPS estimates for 3 consecutive quarters. The next BCAB earnings date is expected around September 1, 2026.
Each quarter, investors track BCAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCAB earnings · 5 questionsBioAtla, Inc.'s next earnings report is expected around September 1, 2026. BCAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCAB historically reports after market close (AMC).
BCAB earnings datewhen is BCAB earningsBCAB next earnings datewhen does BCAB report earningsBCAB earnings calendar
▸ Source: FMP · BioAtla, Inc. SEC filings · US GAAP · BioAtla, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026